Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

October 29, 2024

Overview

Alithea Biotechnology was founded in 2019 by Fanny Giannou and Tim Fugmann to support Biopharma globally on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery. In addition, HLA-Compass is Alithea's cloud-accessible HLA peptide database featuring the measurement of a total of 1.4 Million HLA peptides in 4160 healthy tissue, tumor tissue and cancer cell line samples for target validation and off-target toxicity prediction.

Why to join this webinar:

The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample
Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process
The time is ripe to bring immunopeptidomics into clinical routine

watch on demand

Speaker

Tim Fugmann, Ph.D., Chief Scientific Officer and Co-Founder, Alithea Biotechnology GmbH, Berlin, Germany

Tim Fugmann got his Ph.D. from ETH Zurich, on mass-spectrometric discovery of antibody targets and disease biomarkers. Later, he was leading the target discovery efforts at Philochem, before moving to the Max-Delbrueck-Centrum for Molecular Medicine in Berlin. He was later appointed professor for MS-based proteomics at JLU Giessen. In 2019 he co-founded Alithea Bio UG, which is focusing on immunopeptidomics, a topic which Tim Fugmann studied since 2012.

For Research Use Only. Not for use in clinical diagnostic procedures.